Geron Corporation (Nasdaq: GERN) — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. The filing was signed May 2, 2024. Geron is a late-stage biopharmaceutical company developing imetelstat for hematologic malignancies; it had no product sales and reported only licensing-related royalties.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue (royalties) | $0.304 million | $0.021 million |
| Research and development | $29.4 million | $27.2 million |
| General and administrative | $27.1 million | $12.9 million |
| Total operating expenses | $56.4 million | $40.1 million |
| Net loss | $55.4 million | $38.1 million |
| Basic and diluted loss per share | $0.09 | $0.07 |
| Net cash used in operating activities | $62.3 million | $46.4 million |
| Interest income / expense | $4.2 million / $3.4 million | $3.9 million / $1.9 million |
Gross margin was not reported; royalty revenue was small relative to operating expenses, so a product-margin comparison is not meaningful. The company attributed higher R&D costs mainly to imetelstat manufacturing timing and added personnel. G&A increased primarily due to approximately $11.9 million in higher personnel-related expenses as it prepared for a potential commercial launch.
At March 31, cash and cash equivalents were $189.8 million, restricted cash $1.1 million, and marketable securities $274.1 million, totaling approximately $465.0 million. Total assets were $482.1 million, current liabilities $123.2 million, and stockholders’ equity $344.9 million. Accumulated deficit was $1.65 billion. The company reported $80.0 million of debt principal outstanding; its balance-sheet debt carrying value was $82.7 million, including accrued end-of-term charges and net of unamortized discounts and issuance costs.
Operating cash use was partly offset by $34.2 million of net cash provided by investing activities and $147.8 million provided by financing activities. Financing included $141.0 million net proceeds from a March public offering. Cash, cash equivalents and restricted cash increased by $119.7 million to $190.9 million; this figure excludes marketable securities.
Material changes versus the prior comparable period
- Net loss increased by $17.3 million, while operating expenses rose $16.3 million year over year. G&A more than doubled as commercial preparations advanced.
- Operating cash use increased by $15.9 million, reflecting commercialization preparation, increased headcount, and higher clinical-trial-related payments.
- Interest expense rose $1.5 million, primarily reflecting higher interest rates and debt-related costs.
- Cash, cash equivalents, restricted cash and marketable securities increased from $378.1 million at year-end 2023 to $465.0 million, principally due to the March offering.
- The March offering issued 42.0 million common shares and pre-funded warrants for 8.0 million additional shares. The company recorded $141.0 million in net proceeds, before any future warrant exercise proceeds.
Outlook, developments and key risks
- U.S. regulatory review: The FDA’s advisory committee voted 12–2 on March 14, 2024 that imetelstat’s benefits outweighed its risks for the proposed lower-risk MDS indication. The FDA is not bound by the vote. The PDUFA action date was June 16, 2024. The company said FDA review of clinical, nonclinical and chemistry, manufacturing and controls materials was ongoing and manufacturer inspections had not yet been scheduled. FDA questions included the overall-survival hazard ratio; approval, timing and label remained uncertain.
- Europe: Geron submitted an MAA for the same proposed indication, validated for review in September 2023. It expected review could be completed in early 2025 and, subject to approval, a potential EU launch in 2025.
- Other trials: IMpactMF, a Phase 3 trial in relapsed/refractory myelofibrosis, reached 50% enrollment in November 2023. Based on current enrollment and event assumptions, the company expected an interim overall-survival analysis in early 2026 and a final analysis in early 2027. IMproveMF and investigator-led IMpress were also ongoing.
- Cash runway and funding: Management estimated current resources, together with projected U.S. imetelstat sales if approved, potential warrant proceeds and potential debt drawdowns, could fund projected requirements into Q2 2026. This estimate depends on regulatory approval, commercialization, financing availability and other assumptions. The company said it would still need substantial additional funding to advance the broader program, even if lower-risk MDS approval and commercialization occur.
- Debt: The $80 million principal loan matures April 1, 2025, with a floating rate subject to a 9% minimum. Interest-only payments were scheduled through June 30, 2024, with a possible extension to year-end subject to milestones and capitalization requirements. Up to $45 million of additional tranches remained subject to conditions, including regulatory milestones and lender approval for the final tranche.
- Clinical and manufacturing risks: Imetelstat is Geron’s sole product candidate. The filing identifies significant risks including serious adverse events, particularly thrombocytopenia and neutropenia; reliance on third-party manufacturers and trial vendors; and potential manufacturing or regulatory delays. Geron disclosed that recent FDA inspections identified deficiencies at one manufacturer that could affect its ability to produce or deliver products if not remediated; the filing said the deficiencies were not directly related to imetelstat production.
- Other matters: Previously disclosed securities and derivative lawsuits were settled, with no related liability outstanding at March 31, 2024. The company warned that future litigation, financing needs, dilution, competition, reimbursement and market acceptance could affect its prospects. It also disclosed two service-provider security incidents in 2024 and said it believed neither had a material impact; in one case involving UK personnel data, it notified the UK Information Commissioner’s Office and potentially affected individuals.
Most important facts for investors to verify
- FDA’s decision, timing and final label for imetelstat, including resolution of overall-survival questions and completion of manufacturing inspections.
- Whether EU review progresses on the expected timeline and what approval or launch requirements apply.
- Actual operating cash burn and whether the stated Q2 2026 runway assumptions remain achievable without approval, sales, warrant exercises or conditional debt drawdowns.
- Debt repayment and interest obligations, covenant compliance, and availability of the remaining loan tranches.
- Clinical progress and safety in IMpactMF, IMproveMF and IMpress, plus remediation of manufacturer inspection deficiencies and reliable supply for trials or a potential launch.
- Potential dilution from the March offering, outstanding pre-funded warrants and other warrants. The filing reported 593.1 million common shares outstanding on April 26, 2024; weighted-average Q1 shares were 603.5 million, including pre-funded warrants in the loss-per-share calculation.